Affected Systems |
|
|
|
|
|
cardiovascular system
|
|
√
|
|
√
|
abnormal tumor vascularization
|
|
√
|
|
|
abnormal blood-brain barrier function
|
|
|
|
√
|
hematopoietic system
|
|
√
|
√
|
|
abnormal lymphocyte physiology
|
|
|
√
|
|
abnormal macrophage physiology
|
|
√
|
|
|
homeostasis/metabolism
|
|
√
|
√
|
√
|
decreased circulating interleukin-1 beta level
|
|
|
√
|
|
impaired febrile response
|
|
|
√
|
|
decreased susceptibility to injury
|
|
√
|
|
√
|
immune system
|
N
|
√
|
√
|
|
immune system phenotype
|
N
|
|
|
|
abnormal lymphocyte physiology
|
|
|
√
|
|
abnormal macrophage physiology
|
|
√
|
|
|
decreased circulating interleukin-1 beta level
|
|
|
√
|
|
decreased interferon-gamma secretion
|
|
|
√
|
|
decreased interleukin-1 beta secretion
|
|
√
|
|
|
decreased interleukin-2 secretion
|
|
|
√
|
|
decreased interleukin-4 secretion
|
|
|
√
|
|
abnormal interleukin-6 secretion
|
|
|
√
|
|
decreased tumor necrosis factor secretion
|
|
√
|
|
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
|
|
√
|
|
decreased inflammatory response
|
|
|
√
|
|
decreased acute inflammation
|
|
|
√
|
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
|
√
|
|
|
decreased susceptibility to viral infection
|
|
√
|
|
|
decreased susceptibility to Togaviridae infection
|
|
√
|
|
|
decreased susceptibility to Togaviridae infection induced morbidity/mortality
|
|
√
|
|
|
mortality/aging
|
|
√
|
√
|
|
increased susceptibility to bacterial infection induced morbidity/mortality
|
|
√
|
|
|
decreased susceptibility to Togaviridae infection induced morbidity/mortality
|
|
√
|
|
|
decreased susceptibility to induced morbidity/mortality
|
|
√
|
√
|
|
neoplasm
|
|
√
|
|
|
abnormal tumor vascularization
|
|
√
|
|
|
decreased metastatic potential
|
|
√
|
|
|
decreased tumor growth/size
|
|
√
|
|
|
nervous system
|
|
|
|
√
|
abnormal blood-brain barrier function
|
|
|
|
√
|